VTVT News and Press, vTv Therapeutics Inc. From 10/30/19

vTv Therapeutics (NASDAQ: VTVT ): Q3 Non-GAAP EPS of -$0.10; GAAP EPS of -$0.13 misses by $0.07 . More news on: vTv Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SimpliciT-1 Study of TTP399 in patients with type 1 diabetes fully-enrolled Elevage Study of azeliragon in patients with mild Alzheimer’s disease with type 2 diabetes actively enrolling HIGH POINT, N.C., Oct. 30, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT)...

HIGH POINT, N.C., Oct. 03, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), today announced that the Company will host a key opinion leader (KOL) presentation and webcast discussing the type 1 diabetes (T1D) treatment landscape and emerging therapies in New York City&...

Thinly traded nano cap vTv Therapeutics (NASDAQ: VTVT ) perks up  5%  premarket on increased volume in response to additional positive results from its two-part Phase 2 clinical, Simplici-T1 , evaluating TTP399 for adjunctive treatment of type 1 diabetes (T1D). The data were pre...

HIGH POINT, N.C., Sept. 18, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), today presented additional positive data from its phase 2 Simplici-T1 study in patients with type 1 diabetes (T1D) at the 55th Annual Meeting of the European Association for the Study of Diab...

Noteworthy events during the week of September 15 - 21 for healthcare investors. More news on: CRISPR Therapeutics AG, Pluristem Therapeutics Inc., GlaxoSmithKline plc, Healthcare stocks news, , Read more ...

As the US Department of Health and Human Services notes, Alzheimer’s disease (AD) is a degenerative brain disorder that results in cognitive decline and basic thinking skills which slowly gets worse over time. According to a 2019 Alzheimer’s disease facts and figures re...

 Presenting New Clinical Data from Phase 2 Study in Type 1 Diabetes with Liver Selective GKA Program Pre-Clinical Data in NASH with the NRF2/Bach1 Program  HIGH POINT, N.C., Sept. 11, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharma...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

HIGH POINT, N.C., Sept. 04, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes and Alzheimer’s disease, today announced that it is scheduled to present...